ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,267.84
-0.74%
Dow Jones
39,065.26
-1.53%
US Dollar vs MXN
16.7246
0.36%
Brent Oil
81.325
-0.25%
Bitcoin
68,147.27
-1.38%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
23/05/202416:09Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:BACBank of America Corporation
23/05/202416:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:DXCDXC Technology Company
23/05/202416:08Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ZEOWWZeo Energy Corporation
23/05/202416:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TTMITTM Technologies Inc
23/05/202416:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ODVWZOsisko Development Corporation
23/05/202416:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NCNOnCino Inc
23/05/202416:07Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:KNKnowles Corporation
23/05/202416:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202416:06GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingNASDAQ:GTHXG1 Therapeutics Inc
23/05/202416:05Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:NCNOnCino Inc
23/05/202416:05Business WireAulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
23/05/202416:05GlobeNewswire Inc.Elcora Announces Share ConsolidationTSXV:ERAElcora Advanced Materials Corp
23/05/202416:05GlobeNewswire Inc.Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024NASDAQ:AFMDAffimed NV
23/05/202416:05Business WireBristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research PlatformsNYSE:BMYBristol Myers Squibb Co
23/05/202416:05PR Newswire (US)EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
23/05/202416:05PR Newswire (US)Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
23/05/202416:05PR Newswire (US)IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
23/05/202416:05PR Newswire (US)ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024TSX:ATDAlimentation Couche Tard Inc
23/05/202416:05GlobeNewswire Inc.FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical OncologyNASDAQ:FGENFibroGen Inc
23/05/202416:05PR Newswire (Canada)ALIMENTATION COUCHE-TARD DIFFUSERA LE 25 JUIN PROCHAIN LES RÉSULTATS DE SON QUATRIÈME TRIMESTRE ET DE SON EXERCICE 2024TSX:ATDAlimentation Couche Tard Inc
23/05/202416:05Business WireTelevisaUnivision Announces Pricing of $1.0 Billion Debt
23/05/202416:05GlobeNewswire Inc.Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual MeetNASDAQ:CMPXCompass Therapeutics Inc
23/05/202416:05GlobeNewswire Inc.Cogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerNASDAQ:COGTCogent Biosciences Inc
23/05/202416:05Business WireBicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
23/05/202416:05GlobeNewswire Inc.I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024NASDAQ:IMABI MAB
23/05/202416:05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
23/05/202416:05Business WireTIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in GermanyNASDAQ:NVCRNovoCure Ltd
23/05/202416:04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
23/05/202416:04Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:PRVAPrivia Health Group Inc
23/05/202416:04Business WireBNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution

Su Consulta Reciente

POLO
CAPOUSDT
ILCAPO
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados